🇺🇸 FDA
Patent

US 11780931

CD47 targeted therapies for the treatment of infectious disease

granted A61KA61K2039/505A61K38/1774

Quick answer

US patent 11780931 (CD47 targeted therapies for the treatment of infectious disease) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505, A61K38/1774, A61P, A61P31/12